Review Article

PEMPHIGUS VULGARIS: AN UPDATE ON ETIOPATHOGENESIS, CLINICAL MANIFESTATIONS, DIAGNOSIS AND TREATMENT MODALITIES
Shamimul Hasan 1*, Sameer Ahmad 2, Ravi Kiran 3
1Assistant Professor, Department of Oral Medicine and Radiology, Faculty of Dentistry, Jamia Millia Islamia, New Delhi
2Reader, Department of Periodontology, Darshan dental college and Hospitals Udaipur, Rajasthan, India
3Professor & Head of Department, Department of Periodontology, Darshan dental college and Hospitals Udaipur, Rajasthan, India
*Corresponding Author Email: shamim0571@gmail.com

Article Received on: 21/12/18 Approved for publication: 30/01/19

DOI: 10.7897/2230-8407.100369

ABSTRACT

Pemphigus Vulgaris is an autoimmune, mucocutaneous disorder characterized by occurrence of multiple chronic ulcerations. Although exact etiology is still obscure, the underlying pathogenesis in Pemphigus vulgaris involves autoimmune attack on the epithelial cell adhesion molecules, namely desmosomes and hemidesmosomes. Oral lesions generally appear before the onset of skin lesions, and in 60-70% cases, oral lesions may be the only presenting symptoms. The initial oral lesions manifest as thin walled flaccid bullae, which eventually rupture, leading to formation of large erosive lesions. Early and accurate diagnosis is extremely essential and entails a meticulous history taking, thorough oral and systemic examination along with characteristic histopathology and immunofluorescence features. Although corticosteroids are still the cornerstone of pharmacotherapy, a number of emerging therapies have also evolved with good results.

KEYWORDS: Acantholysis, corticosteroids, erosions, pemphigus, nikolsky sign

INTRODUCTION

Pemphigus refers to a group of autoimmune epithelial blistering mucocutaneous disorder and the term pemphigus is a derivative from the Greek word Pemphix (blister or bubble) 1,2.

Pemphigus vulgaris (PV) is the most frequently seen type of pemphigus in Europe and North America 3. Pemphigus foliaceus, a different type of pemphigus is further subtyped as idiopathic pemphigus foliaceus, drug induced pemphigus foliaceus, pemphigus erythematosus (scear usher syndrome) and endemic pemphigus foliaceus or fogo selvage (endemic to Brazil and Columbia).

Pemphigus vegetans is a subtype of pemphigus vulgaris associated with excessive granulation tissue and crusting 4. Paraneoplastic pemphigus is associated with underlying malignancies 5.

Acantholysis is a distinguishing histologic picture of the pemphigus group, with formation of characteristic intra-epithelial bullae 6. There is histological difference in the acantholysis pattern in Pemphigus vulgaris and pemphigus foliaceus. Acantholysis occurs in the lower stratum spinosum in pemphigus vulgaris, however, pemphigus foliaceus is associated with acantholysis occurring more superficially in the stratum spinosum 7.

Pemphigus vulgaris is a chronic, intra-epithelial vesiculo-bullous disease with a potentially lethal outcome 8, and described initially by Wickman in 1791 9. Highlighting features of pemphigus vulgaris are-chronic course, and vesiculo-bullous eruptions and eventual erosions involving the muco-cutaneous surfaces 10. High mortality rates are linked with geriatric patients and in individuals necessitating corticosteroid doses who develop infections and bacterial septicemia, mostly from Staphylococcus aureus (fluid and electrolyte loss) 11.

ETIOPATHOGENESIS

The exact etiology of PV is obscure. PV may have a genetic predilection due to its association with certain ethnic groups (Ashkenazi Jews and people of Mediterranean people) 12.

Various predisposing factors are-
1. Diet: Diet has been mentioned as an etiological agent in few studies 13,14, however, excessive garlic intake may be associated with few reported pemphigus cases 15.
2. Drugs: A wide array of drugs may also induce pemphigus lesions.

<table>
<thead>
<tr>
<th>Angiotensin-converting enzyme (ACE) inhibitors</th>
<th>Thiol antibiotics</th>
<th>Anti-inflammatory drugs</th>
<th>Miscellaneous</th>
</tr>
</thead>
<tbody>
<tr>
<td>Captopril</td>
<td>Cefalosporin</td>
<td>Aspirin</td>
<td>Levodopa</td>
</tr>
<tr>
<td>Cilazapril</td>
<td>Penicillamine</td>
<td>NSAIDs</td>
<td>Nifedipine</td>
</tr>
<tr>
<td>Enalapril</td>
<td>Penicillin (benzyli)</td>
<td></td>
<td>Propranolol</td>
</tr>
<tr>
<td>Fosinopril</td>
<td></td>
<td></td>
<td>Rifampicin</td>
</tr>
<tr>
<td>Ramipril</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Shamimul Hasan et al. Int. Res. Pharm. 2019, 10 (3)
PV pathogenesis involves an autoimmune attack against desmosomes and hemidesmosomes accountable for epithelial cell adherence. Desmogleins are the proteins that are reactive to autoimmune antibodies in PV. Enzyme-linked immunosorbent assay (ELISA) techniques can demonstrate circulating antibodies involving desmogleins. Three types of desmoglein proteins are demonstrable in stratified squamous epithelium (type 1, 2 and 3). In skin and mucosa, desmoglein type 1 is expressed on the same cell. It has been suggested that the distribution and expression levels of Dsg1 and Dsg3 might account for the characteristic blisters distribution and localization in PV and PF patients. Microscopic studies have demonstrated the expression of Dsg 3 all through the oral mucous membranes, more pronounced in the upper two-thirds. However, the expression of Dsg 3 is limited to the basal and immediate suprabasal layers in the epidermis. This is in contrast to Dsg1, which is expressed throughout the epidermis and oral mucosa, but more pronounced expression occurs in the subcorneal layer and very feeble in the deep epidermis. (Fig 1: A1,B1). The antidesmoglein autoantibody profile in PV is responsible for the respective clinical phenotype. Some PV patients may demonstrate anti-Dsg3 IgG, whereas both anti-Dsg3 and anti-Dsg1 IgG may be demonstrated in other PV patients. However, only anti-Dsg1 IgG have been noticed in patients with PF. The specific site for blister formation in PV may be well explained by the expression of anti-Dsg1 IgG and anti-Dsg3 IgG (Fig 1: A1,B1). This also explains the reason of acantholysis occurring in the deepest mucosal layers (minimal Dsg1 expression) and not in the cutaneous layers (High Dsg1 expression) (Fig. 1: A2, B2). Hence, only oral erosive lesions occurs with no apparent cutaneous lesions in Mucosal dominant Pemphigus Vulgaris. Moreover, both anti-Dsg1 and anti-Dsg3 antibodies may be demonstrated in Mucocutaneous PV, thus, ‘low acantholysis’ in the epidermis may also take place (Fig 1: A3, B3). It is not clear that why the split occurs just above the basal layer instead of the whole epithelium falling apart. However, fewer desmosomes between the basal and the immediate suprabasal layers may be suggested as a reason for a weaker the cell–cell adhesion in this epidermis part. The autoantibodies penetrating from the demis may have an improved entry to the the lower part of the epidermis, thus, explaining the suprabasilar splits in mucocutaneous PV.

3. Viruses-Viruses have been implicated as a possible etiologic factor as some fogo selvagem variant of pemphigus has contagious character. Herpes virus infections has been linked with PV lesions, and the proposed primary pathogenesis involves epitope spreading or molecular impersonation. Human herpes virus 8 (HHV-8) DNA has been isolated in individuals with PV lesions.

4. Miscellaneous factors-Other precipitating factors associated with PV are- imprudent pesticides exposure and increased episodes in pregnancy, thus, highlighting the role of estrogens in the disease pathogenesis.

The differing sites of involvement noted clinically can be elegantly explained by the theory of desmoglein (DSG) compensation. Dsg1 and Dsg3 compensate their adhesive function when co-expressed on the same cell. It has been suggested that the distribution and expression levels of Dsg1 and Dsg3 might account for the characteristic blisters distribution and localization in PV and PF patients. Microscopic studies have demonstrated the expression of Dsg 3 all through the oral mucous membranes, more pronounced in the upper two-thirds. However, the expression of Dsg 3 is limited to the basal and immediate suprabasal layers in the epidermis. This is in contrast to Dsg1, which is expressed throughout the epidermis and oral mucosa, but more pronounced expression occurs in the subcorneal layer and very feeble in the deep epidermis. (Fig 1: A1,B1). The antidesmoglein autoantibody profile in PV is responsible for the respective clinical phenotype. Some PV patients may demonstrate anti-Dsg3 IgG, whereas both anti-Dsg3 and anti-Dsg1 IgG may be demonstrated in other PV patients. However, only anti-Dsg1 IgG have been noticed in patients with PF. The specific site for blister formation in PV may be well explained by the expression of anti-Dsg1 IgG and anti-Dsg3 IgG (Fig 1: A1,B1). This also explains the reason of acantholysis occurring in the deepest mucosal layers (minimal Dsg1 expression) and not in the cutaneous layers (High Dsg1 expression) (Fig. 1: A2, B2). Hence, only oral erosive lesions occurs with no apparent cutaneous lesions in Mucosal dominant Pemphigus Vulgaris. Moreover, both anti-Dsg1 and anti-Dsg3 antibodies may be demonstrated in Mucocutaneous PV, thus, ‘low acantholysis’ in the epidermis may also take place (Fig 1: A3, B3). It is not clear that why the split occurs just above the basal layer instead of the whole epithelium falling apart. However, fewer desmosomes between the basal and the immediate suprabasal layers may be suggested as a reason for a weaker the cell–cell adhesion in this epidermis part. The autoantibodies penetrating from the demis may have an improved entry to the the lower part of the epidermis, thus, explaining the suprabasilar splits in mucocutaneous PV.

![Figure 1](image_url)

**Figure 1.** (A1, B1) Explanation of localization of vesicle formation in classic pemphigus by desmoglein compensation theory. The coloured triangles represent the distribution of desmoglein (Dsg1) and desmoglein 3 (Dsg 3) in the skin and mucous membrane. Pemphigus folaeceus sera contain only anti Dsg 1, which causes superficial blisters in the skin because Dsg3 functionally compensates for the impaired Dsg 1 in the lower part of the epidermis (A 1), whereas those antibodies do not cause blisters in the mucous membranes because cell-cell adhesion is mainly mediated by Dsg3 (B1).
CLINICAL MANIFESTATIONS

PV frequently involve the mucocutaneous sites, resulting in superficial blisters and persistent ulcerative lesions. Multiple mucosal sites are affected, namely, ocular mucosa, oral mucosa, nasal mucosa, pharyngeal and laryngeal mucosa, upper respiratory tract mucosa and ano-genital mucosa.

The hallmark clinical picture of PV consist of thin walled vesiculo-bullous lesions, which eventually ruptures leading to formation of erosive lesions.

A diagnostic clinical test in evaluating patients with signs of oral ulcerations is known as Nikolsky's sign. The test is named after Pyotr Vasilyewich nikolsky, who first described this sign in 1896. Nikolsky's sign involves formation of a lesion after gentle mechanical manipulation (blowing air / applying pressure with mirror handle) on the involved tissue. Wet and dry nikolsky's sign are usually the two forms appreciated. Wet nikolsky's sign in associated with a glistening, moist, and exudative base of eroded skin, indicating an active disease. However, in the dry nikolsky's sign, after the epidermis is separated, the base of eroded skin is relatively dry, indicative of re-epithelization underneath a remnant blister top. A positive Nikolsky’s sign is not limited to PV, and Mucus membrane pemphigoid (MMP), toxic epidermal necrolysis, epidermolysis bullosa and staphylococcal scalded skin syndrome may also present with positive Nikolsky’s sign. A Danish dermatologist, Gustav Asboe-Hansen was the first to describe another peculiar sign (Asboe-Hansen sign) in PV in 1960. Asboe-Hansen sign, also termed as blister-spread sign, refers to the peripheral extension of the blister when mechanical pressure is applied on the roof of the intact blister.

ORAL MANIFESTATIONS

The oral mucosa is frequently involved early in the disease course, and may be the only involved site in few cases of affected patients with PV report oral lesions sometime during the disease process. However, the oral lesions may be the only manifesting feature in more than 60% patients. Oral lesions are initially vesiculobullous, readily burst readily, and new bullous...
lesion develops as the older ones rupture and ulcerate. (Figure 2) The ulcerative and erosive lesions are the key manifestations and are seen mainly on the buccal mucosa, palate, and lips. (Figures 3-6) Pemphigus should always be given a place in the differential diagnosis of chronic, multiple oral erosions.

Gingival lesions initially manifest as isolated blisters or areas of tissue sloughing, but severe desquamative lesions may be appreciated in the advanced stages. (Figure 7) Positive Nikolsky’s sign is seen, and few cases presents with desquamative gingivitis as the only presenting sign.

**DIAGNOSIS**

The diagnosis of Pemphigus vulgaris is based on 3 independent sets of criteria: clinical features, histology and immunological tests.Exclusive oral PV presents diagnostic dilemmas and the diagnosis is established using histopathologic and direct immunofluorescence (DIF) studies. Clinical diagnosis- Nikolsky’s sign may serve as a diagnostic tool in PV patients, but this is neither completely sensitive nor specific.

Histological features- The classic histological feature seen in pemphigus is acantholysis, which is loss of cell-to-cell contact in the epithelial cell layers. In PV, intercellular edema results in dissolution of intercellular bridges and widening of intercellular spaces. This results in separation between cells and formation of blister above basal cell layer (suprabasilar split).

Tzanck preparation- The base of blister is scrapped and examined for acantholytic cells. The free floating ovoid or rounded acantholytic cells have an enlarged, hyperchromatic centrally or eccentrically placed nucleus. Basal cells have tight attachment to basal lamina but gets detached from one another, producing a characteristic tomb stone appearance. Relatively fewer inflammatory cells are seen in PV compared with other bullous diseases.

Compressed air test- Application of a stream of compressed air to the oral mucous membrane of gingival tissues may cause a shimmering of the outer tissues followed by formation of a bleb or blister.

Direct Immunofluorescence- Antibodies that complement various immunoglobulins, most commonly IgG are revealed. This reaction is found intracellularly in epithelium, and creates a distinctive direct immunofluorescence appearance, referred to as chicken wire effect. (Figure 10)
Antibody Binding of rituximab to CD 20 results in complement specific mouse and human monoclonal antibodies (mAbs) which may lead to an autoimmune response which require autoreactive helper T cells. Emerging evidence shows that rituximab is effective in steroid resistant PV. Intravenous Immunoglobulins have proved successful & safe in PV patients when combined with intravenous cyclophosphamide and dexamethasone. In refractory cases are treated by rituximab, plasmapheresis, cyclosporine 40–45 mg/kg/day, and methotrexate 10-17.5 mg/week. Refractory cases are treated by rituximab, plasmapheresis to reduce the presence of antibodies in serum samples, or pulse therapy comprising intravenous cyclophosphamide combined with dexamethasone at high doses. Intravenous Immunoglobulins: Proved successful & safe in steroid resistant PV.

**TREATMENT**

Periodontal therapy is an essential part of overall treatment of pemphigus. Oral hygiene maintenance is mandatory because the gingival involvement may present an exaggerated response to bacterial plaque. Oral lesions pose a therapeutic challenge due to chronic trauma to the surface epithelium during mastication.

The pharmacotherapy aims to combat the disease exacerbations as early as possible. Corticosteroids have a proven efficacy as a therapeutic agent in PV patients, thereby, restoring the marked discrepancy of Tc1/Tc2 (helper T – T suppressor) ratio. In patients with non-progressing oral lesions, topical corticosteroids such as 0.05% fluocinolone acetonide or 0.05% clobetasol propionate are recommended. Patients on long term steroid treatment are monitored for weight gain and advised low salt, low fat, low calorie diet. PV patients are often prescribed Dapsone (125-150 mg daily) or tetracycline (2 g/day) and cotrimoxazole (1.5 g/day). Combination therapy: Combining corticosteroids with immune-suppressive agents (azathioprine, methotrexate, and cyclosporine) allows use of much smaller steroid doses, thus, reducing the steroid-related complications.

Plasminogen activators (tranylcyromide) prevent conversion of plasminogen to plasmin, and are quite beneficial in treating pemphigus. Other options are chloramblucil 0.1-0.15 mg/kg/day, cyclosporine 5-8 mg/kg/day, mycophenolate mofetil 30-45 mg/kg/day, and methotrexate 10-17.5 mg/week. Refractory cases are treated by rituximab, plasmapheresis to reduce the presence of antibodies in serum, or pulse therapy comprising intravenous cyclophosphamide combined with dexamethasone at high doses. Intravenous Immunoglobulins: Proved successful & safe in steroid resistant PV.

**Emerging therapies**

Cholinergic agonists (modulates autoimmune response which require autoreactive helper T cells that regulate IgG isotype switching), Rituximab (Anti CD20 monoclonal antibody), Proteinase inhibitors, and chimeric molecules. Rituximab belongs to the class of biologicals and is a specific mouse and human chimeric monoclonal antibody. Binding of rituximab to CD 20 results in complement- and antibody-dependent cytotoxicity and subsequent apoptosis of cells exhibiting this antigen. Chimeric molecules enables the recognition and elimination of autoimmune B cells which targets Dsg3 specific T cells.

**CONCLUSION**

Pemphigus vulgaris, an autoimmune mucocutaneous disorder is typified clinically by thin walled flaccid vesicles and bullae, eventually leading to multiple erosive lesions, and histopathologically by intra-epithelial blisters. Oral lesions generally precede the cutaneous lesions and remain persistent for a relatively longer time due to unrelentless trauma. Early and accurate diagnosis of oral lesions is essential for an effective treatment protocol. Although, corticosteroids form the baseline of pharmacotherapy, newer treatment options are also being explored with excellent therapeutic potential.

**REFERENCES**

18. Takahashi I, Kobayashi TK, Suzuki H, Nakamura S, Tezuka F. Coexistence of pemphigus vulgaris and herpes simplex virus infection in oral mucosa diagnosed by cytology,
40. Director W. Pemphigus vulgaris: A clinicopathological study. AMA Archives of Dermatology and Syphilology 1992;65(2);155-169.


Source of support: Nil, Conflict of interest: None Declared

Disclaimer: IRJP is solely owned by Moksha Publishing House - A non-profit publishing house, dedicated to publish quality research, while every effort has been taken to verify the accuracy of the content published in our Journal. IRJP cannot accept any responsibility or liability for the site content and articles published. The views expressed in articles by our contributing authors are not necessarily those of IRJP editor or editorial board members.